Inclusion Criteria:

• Have active, relapsed or refractory AML. Active, relapsed or refractory AML is defined as any one of the following:
  • primary induction failure (PIF) after 2 or more cycles of therapy; or
  • first early relapse after a remission duration of fewer than 6 months; or
  • relapse refractory to salvage combination therapy; or
  • second or subsequent relapse (Schmid, 2006).
• Have documented CD45 expression by leukemic cells via flow cytometry (a “blast gate” on CD45 vs. side scatter analysis consist.nt with AML);
• Be ≥ 55 years of age.
• Have a circulating blast count of less than 10,000/mm^3 (control with hydroxyurea is allowed).
• Have a calculated creatinine clearance (Cockroft-Gault equation) > 50 mL/min.
• Have adequate hepatic function (direct bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), defined as ≤ 2 times the upper limit of normal [ULN]).
• Have a Karnofsky score ≥ 70.
• Have an expected survival of > 60 days.
• Have a central venous catheter line in place prior to study treatment administration.
• Have 8/8 allele-level, related or unrelated, HSC donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB1 with a donor who is medically cleared.
• Syngeneic donors that meet these criteria are allowed.
• Women of childbearing potential, be surgically sterile or agree to practice abstinence or utilize acceptable contraception (intrauterine, injectable, transdermal, or combination oral contraceptive) through 1-year post transplant; Males who are sexually active with women of childbearing potential must be surgically sterile or using an acceptable method of contraception (defined as barrier methods in conjunction with spermicides) from time of screening through 12 weeks after last dose of study drug.
• Be able to understand the study procedures, agree to participate in the study program, and voluntarily provide written Informed Consent.

Exclusion Criteria: 

• Have circulating HAMA noted on initial screening.
• Have received prior radiation to maximally tolerated levels to any critical normal organ.
• Have active leukemic central nervous system (CNS) involvement, as defined by any leukemic blasts detected in the cerebrospinal fluid (CSF) by morphology or flow cytometry and/or any chloromas detected by CNS imaging.
• Have previously received a HCT (includes both allogeneic and autologous HCT).
• Clinically significant cardiac disease (NYHA Class III or IV); clinically significant arrhythmia; i.e., ventricular tachycardia, ventricular fibrillation, or “Torsade de Pointes”. Myocardial infarction with uncontrolled angina within 6 months, congestive heart failure, or clinically significant cardiomyopathy.
• Have abnormal QTcF (> 450 milliseconds) after electrolytes have been corrected (at least two different ECG readings and at least 15 minutes between readings). Subjects with paced rhythm or prolonged QTcF may be exempt from this exclusion if considered eligible for transplant per treating physician clinical judgment, with optional cardiology consultation.
• Have current or prior positive test results for human immunodeficiency virus (HIV) or hepatitis B (HBV) or C. Subjects who have positive HBV test results due to having been previously vaccinated against hepatitis B, as evidenced by negative hepatitis B surface antigen (HBsAg), negative anti- hepatitis B core protein (HBc) and positive antibody to the HBsAg (anti-HBs) are not excluded; Subjects who have positive hepatitis test results with adequate organ function as defined in the protocol are not excluded.
• Have active serious infection uncontrolled by antibiotics or antifungals.
• Have acute promyelocytic leukemia and the associated cytogenetic translocation t(15;17).
• Have active malignancy within 2 years of entry. Active malignancy is defined as those malignancies requiring treatment with anti-cancer therapy or in the event of indolent malignancies, having measurable disease.  Exceptions to this exclusion include:
  • myelodysplastic syndrome;
  • treated non-melanoma skin cancer;
  • completely resected Stage 0 or 1 melanoma no less than 1 year from resection;
  • carcinoma in situ or cervical intraepithelial neoplasia;
  • successfully treated organ-confined prostate cancer with no evidence of progressive disease based on prostate specific antigen (PSA) levels and are not on active therapy;
• Have a perceived inability to tolerate diagnostic or therapeutic procedures, particularly treatment in radiation isolation.
• Currently receiving any other active investigational agents.